Literature DB >> 22178559

[Community-acquired methicillin-resistant Staphylococcus aureus: Review].

Pascal Del Giudice1, Pierre Tattevin, Jérôme Etienne.   

Abstract

Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) have emerged worldwide. These CA-MRSA are different from classical hospital-acquired MRSA. They share common characteristics: they affect mainly young subjects, without past medical history. The majority of strains produce the Panton-Valentine leukocidin. They are mainly responsible for suppurative skin infections and rarely for invasive infections such as necrotizing pneumonia. The situation in the US is alarming with a main circulating clone the USA300 clone, whereas in Europe, the diffusion of CA-MRSA strains remains limited. It is important to take advantage of the experience acquired from the US to limit the potential spread of such CA-MRSA strains.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178559     DOI: 10.1016/j.lpm.2011.10.022

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  [Antibiotic susceptibility of community-acquired strains ofstaphylococcus aureus in Nouakchott Region (Mauritania)].

Authors:  Mohamed Lemine Ould Salem; Sidi Mohamed Ghaber; Sidi El Wafi Ould Baba; Mohamed Mahmoud Ould Maouloud
Journal:  Pan Afr Med J       Date:  2016-07-27

2.  Late sequelae of osteoarticular infections in pediatric patients: A single-center study.

Authors:  Lydia Saad; Mathilde Hupin; Chantal Buteau; Marie-Lyne Nault
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

Review 3.  Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.

Authors:  Annaliesa S Anderson; Alita A Miller; Robert G K Donald; Ingrid L Scully; Jasdeep S Nanra; David Cooper; Kathrin U Jansen
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.